Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
A16z Bio+health
BioCentury | Sep 19, 2024
Finance
Series A cash for Brenus, GCTx, Nura among week’s VC highlights
Also in BioCentury’s latest Venture Report: New investment initiatives from Novo and RA Capital
BioCentury | Sep 19, 2024
Emerging Company Profile
GCTx: Simplifying iPSC-based cell therapy production
Launching with $75M, Cambridge, Mass. start-up aims to shortcut the cell therapy manufacturing process by directly activating transcription factors involved in cell fate
BioCentury | Aug 9, 2024
Finance
Venture Report: Pair of crossover rounds for precision oncology, peptide biotechs
Plus: Financings for newcos Nilo, Jade, Red Queen
BioCentury | Jun 13, 2024
Emerging Company Profile
Santa Ana: Leveraging human multi-omic data for precision immunology
Versant-founded immunology play launches with $168M to create biologics targeted to specific cell types
BioCentury | Dec 13, 2023
Finance
Dec. 12 Quick Takes: Targeted genomic DNA insertion company Tome launches with $213M
Plus: Bicara’s latest big round is a $165M series C, Shinobi launches, Pfizer readies to close Seagen deal and more
BioCentury | Nov 2, 2023
Emerging Company Profile
Gate: selective blockade of pathogenic protein secretion
Gate Bio emerged from stealth with a $60M series A and a small molecule platform for selective gating of protein secretion
BioCentury | Sep 21, 2022
Emerging Company Profile
Orbital: an RNA toolbox for vaccines and protein replacement therapies
Arch-backed newco unites RNA pioneer Maraganore with technology from Stanford and sister company Beam Therapeutics
BioCentury | Sep 7, 2022
Finance
Sept. 7 Quick Takes: Arch-backed Orbital launches with RNA platform
Plus Arpeggio raises $17M series A for transcriptional mechanisms, and updates from Equillium, BoomRay, Zealand and more
Items per page:
1 - 8 of 8